Published in J Clin Invest on December 01, 1995
Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev (1998) 4.03
A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest (1997) 2.37
IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. J Immunol (2008) 1.79
Location and cellular stages of natural killer cell development. Trends Immunol (2013) 1.59
A primer on cytokines: sources, receptors, effects, and inducers. Clin Microbiol Rev (1997) 1.57
The cytokine network of acute HIV infection: a promising target for vaccines and therapy to reduce viral set-point? PLoS Pathog (2011) 1.33
Human natural killer cells mediate killing of intracellular Mycobacterium tuberculosis H37Rv via granule-independent mechanisms. Infect Immun (2001) 1.27
Natural killer (NK) cells in antibacterial innate immunity: angels or devils? Mol Med (2012) 1.25
Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-derived cytokines. J Clin Invest (1996) 1.23
In vivo regulation of replicative Legionella pneumophila lung infection by endogenous interleukin-12. Infect Immun (1998) 1.11
Interleukin-15 may be responsible for early activation of intestinal intraepithelial lymphocytes after oral infection with Listeria monocytogenes in rats. Infect Immun (1998) 1.07
Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients. Infect Immun (2003) 1.07
Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol (2014) 1.07
Endotoxin-induced gamma interferon production: contributing cell types and key regulatory factors. Clin Diagn Lab Immunol (2002) 1.06
The role of IL-15 deficiency in the pathogenesis of virus-induced asthma exacerbations. PLoS Pathog (2011) 1.05
The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases. Arthritis Res (2002) 1.03
Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br J Cancer (2000) 1.03
Interleukin 12 in part regulates gamma interferon release in human whole blood stimulated with Leptospira interrogans. Clin Diagn Lab Immunol (2003) 1.03
Activation of human NK cells by staphylococci and lactobacilli requires cell contact-dependent costimulation by autologous monocytes. Clin Diagn Lab Immunol (2002) 1.02
Mycobacterium tuberculosis-induced gamma interferon production by natural killer cells requires cross talk with antigen-presenting cells involving Toll-like receptors 2 and 4 and the mannose receptor in tuberculous pleurisy. Infect Immun (2007) 0.99
Hepatic interleuklin 15 (IL-15) expression: implications for local NK/NKT cell homeostasis and development. Clin Exp Immunol (2004) 0.98
Interleukin-15 augments superoxide production and microbicidal activity of human monocytes against Candida albicans. Infect Immun (1998) 0.98
NK cells: immune cross-talk and therapeutic implications. Immunotherapy (2011) 0.96
IFN-γ production by human natural killer cells in response to HCV-infected hepatoma cells is dependent on accessory cells. J Hepatol (2013) 0.94
Inhibition of human NK cell function by valinomycin, a toxin from Streptomyces griseus in indoor air. Infect Immun (2000) 0.93
Cytokine profile during latent and slowly progressive primary tuberculosis: a possible role for interleukin-15 in mediating clinical disease. Clin Exp Immunol (2006) 0.91
The innate interferon gamma response of BALB/c and C57BL/6 mice to in vitro Burkholderia pseudomallei infection. BMC Immunol (2006) 0.91
NK cell activity in tuberculosis is associated with impaired CD11a and ICAM-1 expression: a regulatory role of monocytes in NK activation. Immunology (2005) 0.90
Molecular pathways: interleukin-15 signaling in health and in cancer. Clin Cancer Res (2014) 0.90
Vaccine Development Against Leishmania donovani. Front Immunol (2012) 0.90
Overexpression of Interleukin-15 increases susceptibility to lipopolysaccharide-induced liver injury in mice primed with Mycobacterium bovis bacillus Calmette-Guerin. Infect Immun (2004) 0.90
Studies on the production of IL-15 in HIV-infected/AIDS patients. J Clin Immunol (2003) 0.89
GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder. J Clin Invest (2001) 0.88
Interleukin-15 and NK1.1+ cells provide innate protection against acute Salmonella enterica serovar Typhimurium infection in the gut and in systemic tissues. Infect Immun (2008) 0.85
Interleukin-15 enhances cytotoxicity, receptor expression, and expansion of neonatal natural killer cells in long-term culture. Clin Diagn Lab Immunol (2004) 0.85
A high-efficiency system of natural killer cell cloning. J Immunol Methods (2005) 0.84
Differential effects of interleukin-12, interleukin-15, and interleukin-2 on human immunodeficiency virus type 1 replication in vitro. Clin Diagn Lab Immunol (1996) 0.84
Interleukin-12 enhances antifungal activity of human mononuclear phagocytes against Aspergillus fumigatus: implications for a gamma interferon-independent pathway. Infect Immun (1999) 0.84
Notch signaling at later stages of NK cell development enhances KIR expression and functional maturation. J Immunol (2014) 0.84
In vitro immunologic and virologic effects of interleukin 15 on peripheral blood mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol (1997) 0.83
Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection. J Clin Immunol (1998) 0.83
IL-15 in human visceral leishmaniasis caused by Leishmania infantum. Clin Exp Immunol (2002) 0.81
Effect of interleukin-15 on the course of myocarditis in Coxsackievirus B3-infected BALB/c mice. Can J Cardiol (2009) 0.81
Utilizing IL-12, IL-15 and IL-7 as Mucosal Vaccine Adjuvants. Lett Drug Des Discov (2006) 0.80
Expression of interleukin-15 and interleukin-15Rα in monocytes of HIV type 1-infected patients with different courses of disease progression. AIDS Res Hum Retroviruses (2011) 0.79
Human cord blood γδ T cells expressing public Vγ2 chains dominate the response to bisphosphonate plus interleukin-15. Immunology (2013) 0.79
Host's innate immune response to fungal and bacterial agents in vitro: up-regulation of interleukin-15 gene expression resulting in enhanced natural killer cell activity. Immunology (2003) 0.79
Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. PLoS One (2013) 0.78
Membrane bound IL-15 is increased on CD14 monocytes in early stages of MS. J Neuroimmunol (2008) 0.78
Effect of IL-15 and natural killer cells on osteoclasts and osteoblasts in a mouse coculture. Inflammation (2014) 0.76
Human monocytes have increased IFN-γ-mediated IL-15 production with age alongside altered IFN-γ receptor signaling. Clin Immunol (2014) 0.76
Identification of IFN-γ-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposure. Oncotarget (2016) 0.75
Activation of mononuclear cells by interleukin-12: an in vivo study in chimpanzees. J Clin Immunol (1999) 0.75
Human amniotic fluid lacks interleukin-2 and interleukin-15 but can interact with the beta-chain of the interleukin-2 receptor. Immunology (2000) 0.75
Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review. Pathog Glob Health (2016) 0.75
Induction of IL-15 by TCR/CD3 aggregation depends on IFN-gamma and protects against apoptosis of immature thymocytes in vivo. Clin Exp Immunol (2002) 0.75
T cell interleukin-15 surface expression in chimpanzees infected with human immunodeficiency virus. Cell Immunol (2014) 0.75
MICA-expressing monocytes enhance natural killer cell Fc receptor-mediated antitumor functions. Cancer Immunol Res (2017) 0.75
T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol (1978) 28.92
Biology of natural killer cells. Adv Immunol (1989) 14.77
Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med (1992) 8.27
Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med (1993) 8.03
Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med (1991) 7.52
Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci U S A (1993) 6.87
Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science (1994) 6.65
Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci U S A (1993) 6.33
Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med (1994) 5.20
Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S). J Immunol (1989) 4.20
Biology and clinical relevance of human natural killer cells. Blood (1990) 3.50
Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection. J Exp Med (1994) 3.02
Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med (1990) 2.79
Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha. Infect Immun (1994) 2.48
The role of natural killer cells in innate resistance to infection. Curr Opin Immunol (1993) 2.42
Interleukin 12 in host defense against microbial pathogens. Proc Natl Acad Sci U S A (1993) 2.08
In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii. J Immunol (1985) 2.00
Activation of natural killer cells via the p75 interleukin 2 receptor. J Exp Med (1989) 1.95
Expression of a functional c-kit receptor on a subset of natural killer cells. J Exp Med (1993) 1.45
Leishmania donovani infection in scid mice: lack of tissue response and in vivo macrophage activation correlates with failure to trigger natural killer cell-derived gamma interferon production in vitro. Infect Immun (1992) 1.29
Effector functions of activated macrophages against parasites. Curr Opin Immunol (1993) 1.07
Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10. Blood (1995) 1.03
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 10.14
The biology of human natural killer-cell subsets. Trends Immunol (2001) 10.10
Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature (1985) 9.94
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet (2000) 8.58
Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J (1994) 5.69
Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood (2001) 5.23
Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med (1994) 5.20
Interleukin 15: biology and relevance to human disease. Blood (2001) 4.47
Doublecortin, a brain-specific gene mutated in human X-linked lissencephaly and double cortex syndrome, encodes a putative signaling protein. Cell (1998) 4.44
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J (1997) 4.28
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res (2001) 3.66
Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet (2001) 3.58
Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol (1993) 3.29
Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol (1999) 3.18
Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci U S A (2001) 3.01
Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med (2001) 2.96
Purification to homogeneity of B cell stimulating factor. A molecule that stimulates proliferation of multiple lymphokine-dependent cell lines. J Exp Med (1986) 2.71
Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood (1996) 2.62
Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci (1997) 2.62
Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci (1997) 2.55
A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest (1997) 2.37
Molecular cloning and biological characterization of a novel murine lymphoid growth factor. J Exp Med (2000) 2.21
Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest (1993) 2.18
Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A (2001) 2.16
Proteins bound at adjacent DNA elements act synergistically to regulate human proenkephalin cAMP inducible transcription. EMBO J (1988) 2.15
Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem (1996) 1.89
Characterization of the high-affinity cell-surface receptor for murine B-cell-stimulating factor 1. Proc Natl Acad Sci U S A (1987) 1.83
The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia. Proc Natl Acad Sci U S A (1998) 1.79
Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex. J Neurosci (2000) 1.76
ALL-1 partial duplication in acute leukemia. Proc Natl Acad Sci U S A (1994) 1.74
Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. J Immunol (1990) 1.74
Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. Proc Natl Acad Sci U S A (2000) 1.69
Cyclooxygenase-1 participates in selected vasodilator responses of the cerebral circulation. Circ Res (2001) 1.69
Restricted production of interleukin 4 by activated human T cells. Proc Natl Acad Sci U S A (1988) 1.67
Cloning, sequence, and expression of a human granulocyte/macrophage colony-stimulating factor. Proc Natl Acad Sci U S A (1985) 1.62
Cerebellar histogenesis is disturbed in mice lacking cyclin D2. Development (1999) 1.61
Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. J Immunol (1998) 1.59
LIS1 and XLIS (DCX) mutations cause most classical lissencephaly, but different patterns of malformation. Hum Mol Genet (1998) 1.57
Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. J Immunol (1998) 1.55
Minimal region of loss at 13q14 in B-cell chronic lymphocytic leukemia. Blood (1996) 1.54
Reduced nicotinamide-adenine dinucleotide phosphate dependent biliverdin reductase: partial purification and characterization. Biochemistry (1970) 1.53
ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. Cancer Res (1994) 1.52
Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood (1998) 1.51
Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood (1996) 1.49
BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci U S A (2001) 1.48
Expression of interleukin 2, interferon-gamma, and the IL 2 receptor by human peripheral blood lymphocytes. J Immunol (1986) 1.46
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol (2001) 1.46
Expression of a functional c-kit receptor on a subset of natural killer cells. J Exp Med (1993) 1.45
X-linked malformations of neuronal migration. Neurology (1996) 1.42
Primary extranodal lymphoma: response to treatment and factors influencing prognosis. Cancer (1978) 1.40
Leukemia-associated Rho guanine nucleotide exchange factor, a Dbl family protein found mutated in leukemia, causes transformation by activation of RhoA. J Biol Chem (2001) 1.39
Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood (1994) 1.37
The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. Proc Natl Acad Sci U S A (1994) 1.33
Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J Cereb Blood Flow Metab (1995) 1.31
Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol (1999) 1.30
Inducible nitric oxide synthase gene expression in vascular cells after transient focal cerebral ischemia. Stroke (1996) 1.30
Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc Natl Acad Sci U S A (1998) 1.30
Differences in the gyral pattern distinguish chromosome 17-linked and X-linked lissencephaly. Neurology (1999) 1.29
Recombinant CD40 ligand stimulation of murine B cell growth and differentiation: cooperative effects of cytokines. Eur J Immunol (1993) 1.28
Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol (1996) 1.27
Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene (2007) 1.27
The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood (1995) 1.26
Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-derived cytokines. J Clin Invest (1996) 1.23
Somatic and germline mosaic mutations in the doublecortin gene are associated with variable phenotypes. Am J Hum Genet (2000) 1.22
Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol (2001) 1.20
Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias. Leukemia (2006) 1.19
Mutation analysis of the DCX gene and genotype/phenotype correlation in subcortical band heterotopia. Eur J Hum Genet (2001) 1.19
Fatal leukemia in interleukin-15 transgenic mice. Blood Cells Mol Dis (2001) 1.17
Tumor cell apoptosis, lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever-like) whole body hyperthermia. J Cell Physiol (1998) 1.15
The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab (1999) 1.14
Changing patterns of gene expression define four stages of cerebellar granule neuron differentiation. Development (1993) 1.14
A functional B cell receptor transgene allows efficient IL-7-independent maturation of B cell precursors. J Immunol (1997) 1.13
Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood (1994) 1.12
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia (2012) 1.11
The effect of N-bromosuccinimide on the sub-unit structure of acidin and its complexes with biotin. Biochem J (1968) 1.11
Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia (1998) 1.11
CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur J Immunol (1997) 1.10
Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia. Mol Cell Biol (2000) 1.10
Interleukin-1beta costimulates interferon-gamma production by human natural killer cells. Eur J Immunol (2001) 1.09
The molar tooth sign: a new Joubert syndrome and related cerebellar disorders classification system tested in Egyptian families. Neurology (2008) 1.09
Marked induction of calcium-independent nitric oxide synthase activity after focal cerebral ischemia. J Cereb Blood Flow Metab (1995) 1.08
Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements. J Biol Chem (1996) 1.07
Molecular pathology of cerebral ischemia: delayed gene expression and strategies for neuroprotection. Ann N Y Acad Sci (1997) 1.07
Virus-induced diabetes mellitus. IV. Genetic and environmental factors influencing the development of diabetes after infection with the M variant of encephalomyocarditis virus. Diabetes (1976) 1.07
Crooked tail (Cd) models human folate-responsive neural tube defects. Hum Mol Genet (1999) 1.06
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia (2011) 1.05
Evidence for the existence of homologous gene coding regions for the catecholamine biosynthetic enzymes. Cold Spring Harb Symp Quant Biol (1983) 1.05
A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J Immunol (1999) 1.05
Late-onset Wilson's disease with neurological involvement in the absence of Kayser-Fleischer rings. Ann Neurol (1985) 1.04
Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells. Blood (1997) 1.04
Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia. Acta Neuropathol (1999) 1.04
Increased susceptibility to ischemic brain injury in cyclooxygenase-1-deficient mice. J Cereb Blood Flow Metab (2001) 1.03
Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10. Blood (1995) 1.03